Lynparza

AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment
Yahoo/Reuters
Tue, 06/18/19 - 10:04 am
AstraZeneca
Lynparza
ovarian cancer
Europe
ASCO 2019 day one
Pharmaforum
Fri, 05/31/19 - 11:46 am
ASCO 2019
JNJ
Erleada
AstraZeneca
Merck
Lynparza
prostate cancer
Lynparza on cusp of EU approval for advanced ovarian cancer
Pharmaforum
Mon, 04/29/19 - 10:28 am
AstraZeneca
Lynparza
Europe
CHMP
ovarian cancer
AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast cancer
Pharmaforum
Wed, 04/10/19 - 09:46 am
AstraZeneca
Merck
Lynparza
BRCA-mutant breast cancer
Europe
breast cancer
Early pancreatic cancer data give Clovis a new path in PARP market
Biopharma Dive
Tue, 04/2/19 - 04:22 pm
pancreatic cancer
Clovis Oncology
AstraZeneca
PARP inhibitors
AACR
Rubraca
Lynparza
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
Yahoo/Zacks.com
Thu, 12/20/18 - 10:16 am
Myriad Genetics
AstraZeneca
BRACAnalysis CDx
diagnostics
Lynparza
FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment
Endpoints
Thu, 12/20/18 - 10:01 am
AstraZeneca
Merck
Lynparza
BRCA-mutated ovarian cancer
FDA
FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review
CP Wire
Mon, 11/12/18 - 10:19 am
Lynparza
Merck
AstraZeneca
ovarian cancer
FDA
FDA Accepts sNDA for Lynparza for Maintenance Therapy in Advanced Ovarian Cancer and Grants Priority Review
Mon, 11/12/18 - 09:54 am
Lynparza
Merck
AstraZeneca
ovarian cancer
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Fierce Pharma
Wed, 10/24/18 - 12:38 pm
PARP inhibitors
physicians
Zejula
Rubraca
Lynparza
AstraZeneca
Merck
Tesaro
Clovis Oncology
Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch
Fierce Pharma
Sun, 10/21/18 - 11:33 pm
AstraZeneca
Merck
Lynparza
PARP inhibitors
BRCA-mutated ovarian cancer
AstraZeneca, Merck’s Lynparza gets FDA ODD for pancreatic cancer
Pharmaceutical Business Review
Wed, 10/17/18 - 09:11 am
AstraZeneca
Merck
Lynparza
FDA
pancreatic cancer
orphan drug
Major Expected Events from AstraZeneca’s R&D in H2 2018
Market Realist
Sat, 08/25/18 - 09:24 pm
AstraZeneca
China
Lynparza
Tagrisso
Imfinzi
PARP inhibitors show promise for treating ALS and other brain disorders
Fierce Biotech
Thu, 08/9/18 - 10:04 pm
PARP inhibitors
AstraZeneca
Lynparza
Tesaro
Zejula
ALS
AstraZeneca wins speedy approvals for cancer drugs in Japan
Yahoo/Reuters
Mon, 07/2/18 - 09:23 am
AstraZeneca
Japan
Imfinzi
Lynparza
AstraZeneca, Merck eye wider cancer drug use after study success
Yahoo/Reuters
Wed, 06/27/18 - 09:42 am
AstraZeneca
Merck
Lynparza
ovarian cancer
ASCO: AstraZeneca pioneer Lynparza scores with Zytiga combo in prostate cancer
Fierce Pharma
Tue, 06/5/18 - 10:34 pm
AstraZeneca
Lynparza
prostate cancer
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
CP Wire
Mon, 04/16/18 - 09:04 am
AstraZeneca
Merck
Lynparza
metastatic breast cancer
AACR
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
Mon, 04/16/18 - 01:21 am
AstraZeneca
Merck
Lynparza
HER-2 negative breast cancer
breast cancer
Myriad’s breast cancer diagnostic wins approval in Japan
Drug Delivery Business News
Mon, 04/2/18 - 09:27 am
Myriad Genetics
diagnostics
breast cancer
Japan
Bracanalysis Diagnostic System
Lynparza

Pages